New Pulsed-Field Ablation Device Found Effective at 1 Year On the heels of the first pulsed-field ablation device to win approval for atrial fibrillation ablation, a novel version of the technology ...

Most UK Doctors Lack Confidence in GMC, Survey Finds A majority of UK doctors lack confidence in the GMC’s ability to protect the public, with 82% backing a new regulator focused solely on doctors, ...

Kennedy Replaces Fired US CDC Panel Members, Includes Anti-vaccine Proponents U.S. Health Secretary Robert Kennedy Jr. named eight members to serve on a key panel of vaccine advisers on Wednesday, ...

Jun 27 2025 This Week in Cardiology FDA approves triple-drug polypill, a change of opinion, a deep dive into invasive pulmonary embolism therapies, heart disease trends, and diabetes care is on fire ...

How do you test aha moments in the laboratory? The system is really clever. Participants (90 in this study) were exposed to a very simple computer game during which dots move around a circle in ...

Jun 27 2025 This Week in Cardiology FDA approves triple-drug polypill, a change of opinion, a deep dive into invasive pulmonary embolism therapies, heart disease trends, and diabetes care is on fire ...

How Middlemen Funnel Illegal Chinese Vapes Into the United States From an office a 15-minute drive from Chicago's O'Hare International Airport, one small firm helped import millions of unauthorized ...

Psoriatic Arthritis From the Dermatologist’s Perspective Drs Tina Bhutani, Mona Shahriari, and Jason Hawkes explore how dermatologists are uniquely positioned to identify and manage psoriatic ...

Acute dacryocystitis is common in women, and the risk for the condition rises with age, especially in those with primary acquired nasolacrimal duct obstruction.

EULAR 2025 Meeting Target Serum Urate Level Cuts CV Risk in Gout Gout patients who met a target serum urate level of 360 μmol/L (6 mg/dL) within 12 months of treatment cut their risk for major ...

Can Dose Spacing of IL-17i Maintain Efficacy in Psoriasis? IL-17 inhibitors secukinumab and brodalumab demonstrate similar efficacy in patients with psoriasis for up to a year after dose spacing, ...

A post hoc analysis of the BEATcc trial showed that atezolizumab plus chemotherapy and bevacizumab provided clinical benefit ...